CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the use of bacterially-derived nanocells for targeted drug delivery in cancer treatment. It aims to assess the safety and efficacy of these nanocells while considering individual genetic variations that may influence therapeutic outcomes.
According to the project ‘Fighting against cancer today’ (FACT, funded by the EU 2008), molecularly targeted drugs with associated sophisticated diagnostic systems to personalize care are likely to have a great impact on cancer control in Europe.
At the same time, drug delivery is going to be progressed by nanomedicines that can ferry high amounts of active drugs to the tumor. A recent achievement in developing drug delivery systems are bacterially-derived mini- or nanocells that appear to be su…
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
